AMRI launches its US integrated drug discovery centre

Facility provides customers with a single site for biology, high-throughput screening, in vitro pharmacology and medicinal chemistry



Albany Molecular Research introduces its new US-based integrated drug discovery centre in Buffalo (New York). Located on the Buffalo Niagara Medical Campus and part of the larger commitment by the State of New York with SUNY Polytechnic Institute, this drug discovery centre offers customers leading-edge platforms and capabilities to develop new approaches to discover life-saving therapies.

The centre will increase translation to the clinic by leveraging expertise in biology, high-throughput screening (HTS), medicinal chemistry and pharmacology, all integrated within a single site in the United States.

‘We are excited to launch a realigned and upgraded discovery service offering for our customers through our new centre for global drug discovery in Buffalo,’ said Christopher Conway, Senior Vice President, Discovery and Development, AMRI. ‘AMRI is the only North American-based discovery CRO with biology, pharmacology, HTS and chemistry located in one building, in the centre of a hub of complementary biotech, major medical and academic centres. This hub for drug discovery provides our customers and partners with the speed in decision making and depth of collaboration needed to accelerate speed of data and maximise results.’

AMRI's world-class HTS capabilities include compound and sample management, conventional and next-generation HTS and access to state-of-the-art equipment and readout instruments.

‘The ultimate aim of this site is to provide a suite of discovery services, from assay development and HTS to medicinal chemistry and in vitro pharmacology, that will reduce data cycle times to improve the value of our customers' discovery programmes, as well as offer ease-of-communication with project teams and functional groups,’ said Rory Curtis, Vice President, Discovery Biology and Pharmacology, and Site Head of AMRI Buffalo. ‘AMRI is coupling its broad target-class coverage with state-of-the-art equipment to fulfil unmet needs for our customers when it comes to the expertise and experience they should be receiving from their drug discovery CRO partners.’

Companies